Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Svetlana A. Smirnikhina"'
Autor:
Alexander V. Lavrov, Ekaterina Yu. Chelysheva, Elmira P. Adilgereeva, Oleg A. Shukhov, Svetlana A. Smirnikhina, Konstantin S. Kochergin-Nikitsky, Valentina D. Yakushina, Grigory A. Tsaur, Sergey V. Mordanov, Anna G. Turkina, Sergey I. Kutsev
Publikováno v:
BMC Medical Genomics, Vol 12, Iss S2, Pp 5-13 (2019)
Abstract Background Approximately 5–20% of chronic myeloid leukemia (CML) patients demonstrate primary resistance or intolerance to imatinib. None of the existing predictive scores gives a good prognosis of TKI efficacy. Gene polymorphisms, express
Externí odkaz:
https://doaj.org/article/65b6107f1bb54961af0fe7269e7108aa
Autor:
Olga V. Volodina, Arina A. Anuchina, Milyausha I. Zainitdinova, Nadezhda A. Evtushenko, Alexander V. Lavrov, Svetlana A. Smirnikhina
Publikováno v:
Biochemistry (Moscow). 87:464-471
Gene editing allows to make a variety of targeted changes in genome, which can potentially be used to treat hereditary human diseases. Despite numerous studies in this area, effectiveness of gene editing methods for correcting mutations is still low,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d7feb3646ebbc67b73440e5221ce1ce
https://doi.org/10.1134/s0006297922050078
https://doi.org/10.1134/s0006297922050078
Publikováno v:
Molecular Biotechnology. 65:181-195
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7230f197f9f6320de0dbd7452de496e8
https://doi.org/10.1007/s12033-022-00479-z
https://doi.org/10.1007/s12033-022-00479-z
Autor:
Alexander V Lavrov, Oksana A Ustaeva, Elmira P Adilgereeva, Svetlana A Smirnikhina, Ekaterina Y Chelysheva, Oleg A Shukhov, Yuriy V Shatokhin, Sergey V Mordanov, Anna G Turkina, Sergey I Kutsev
Publikováno v:
PLoS ONE, Vol 12, Iss 9, p e0182901 (2017)
Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the presence of BCR/ABL fusion gene in leukemic cells, which promotes uncontrolled cell proliferation. Up to 20% of CML patients show primary resistance or non-optimal re
Externí odkaz:
https://doaj.org/article/aebeca0cfcc84482b693b260ee7cce6c
Autor:
Arina A. Anuchina, Milyausha I. Zaynitdinova, Anna G. Demchenko, Nadezhda A. Evtushenko, Alexander V. Lavrov, Svetlana A. Smirnikhina
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 7; Pages: 6704
This study aimed to enhance homology-directed repair (HDR) efficiency in CRISPR/Cas-mediated genome editing by targeting three key factors regulating the balance between HDR and non-homologous end joining (NHEJ): MAD2L2, SCAI, and Ligase IV. In order
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18e1f92cfbc6dd835db4c65285f755a5
https://doi.org/10.3390/ijms24076704
https://doi.org/10.3390/ijms24076704
Publikováno v:
Transgenic research. 31(6)
Glycogen storage disease type 1 (GSD1) is a rare hereditary monogenic disease characterized by the disturbed glucose metabolism. The most widespread variant of GSD1 is GSD1a, which is a deficiency of glucose-6-phosphatase-ɑ. Glucose-6-phosphatase-ɑ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bcbfde09e76a0a5cd1da1e62367bfcda
https://pubmed.ncbi.nlm.nih.gov/36006546
https://pubmed.ncbi.nlm.nih.gov/36006546
Publikováno v:
Molecular biotechnology.
The efficient delivery of CRISPR-Cas components is still a key and unsolved problem. CRISPR-Cas delivery in the form of a Cas protein+sgRNA (ribonucleoprotein complex, RNP complex), has proven to be extremely effective, since it allows to increase on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::03ca9c1e5a4dec9aed9aa2d591fb4322
https://pubmed.ncbi.nlm.nih.gov/35322386
https://pubmed.ncbi.nlm.nih.gov/35322386
Autor:
Svetlana A Smirnikhina
Publikováno v:
The CRISPR Journal. 3:319-321
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d24bc53da2f55c29868986d1301d95f
https://doi.org/10.1089/crispr.2020.29105.sas
https://doi.org/10.1089/crispr.2020.29105.sas
Autor:
Svetlana A, Smirnikhina, Milyausha I, Zaynitdinova, Vasilina A, Sergeeva, Alexander V, Lavrov
Publikováno v:
International Journal of Molecular Sciences. 23:5992
Genome editing is currently widely used in biomedical research; however, the use of this method in the clinic is still limited because of its low efficiency and possible side effects. Moreover, the correction of mutations that cause diseases in human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8260df4a7a04a0891a882863fa59065e
https://doi.org/10.3390/ijms23115992
https://doi.org/10.3390/ijms23115992
Autor:
Svetlana A Smirnikhina, Ekaterina V Kondrateva, Elmira P Adilgereeva, Arina A Anuchina, Milyausha I Zaynitdinova, Yana S Slesarenko, Angelina S Ershova, Kirill D Ustinov, Matvei I Yasinovsky, Elena L Amelina, Ekaterina S Voronina, Valentina D Yakushina, Vyacheslav Yu Tabakov, Alexander V Lavrov
Publikováno v:
PLoS ONE, Vol 15, Iss 11, p e0242094 (2020)
Development of genome editing methods created new opportunities for the development of etiology-based therapies of hereditary diseases. Here, we demonstrate that CRISPR/Cas9 can correct p.F508del mutation in the CFTR gene in the CFTE29o- cells and in
Externí odkaz:
https://doaj.org/article/f4049aac3810497094311f456c88b229